Clinical Trials Logo
  1. Home
  2. End Stage Renal Disease
  3. NCT01687699

Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

End-stage Renal Failure Clinical Trial

Clinical Trial Summary

Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis (HD) patients. In the present study, we assess whether low-dose spironolactone treatment reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in HD patients. The investigators' hypothesis is that aldosterone receptor blockade by spironolactone reduces the risk of both CCV morbidity and death among HD patients.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01687699
Study type Interventional
Source Dialysis Outcomes Heart Failure Aldactone Study Group
Contact
Status Completed
Phase Phase 4
Start date April 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT01449266 - Safety and Dialysability of Dotarem® in Dialysed Patients Phase 1
Completed NCT01126905 - Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal Patients
Completed NCT01656135 - Reference Group Trial for The ONE Study Phase 4
Completed NCT00807144 - Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation Phase 4
Active, not recruiting NCT00238043 - Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia Phase 3
Completed NCT02129881 - The ONE Study UK Treg Trial Phase 1/Phase 2